New date for publication of Vigmed Holding AB Interim Report for 1 January – 30 June 2017

The Board of Directors of Vigmed Holding AB have decided to postpone the publication of the Interim Report for 1 January – 30 June 2017, to 30 August 2017.

The report was previously planned to be published on 24 August 2017.

For more information contact:
CEO Henrik Olsen, tel. +46 763-497 364
Board member Georg Heftberger, tel. +43 664 884 106 83

In case of differences between the Swedish and English press releases, the Swedish press release shall prevail.

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ First North in Stockholm (ticker VIG). Remium Nordic AB is the Company’s Certified Advisor. Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor 

Tags:

About Us

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and the company has approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified Advisor. Additional information can be found on Vigmed’s home page: www.vigmed.com

Documents & Links